Aratana Therapeutics has just won the Best Pipeline 2014 Award from the Animal Pharm industry website.

The Kansas City, Kan., company develops treatments to help pets dealing with cancer, arthritis, allergies and other ailments. It has a large portfolio of 18 potential products, and that’s one of the reasons why it was selected for the award.

“Today, Aratana has a diversified pipeline consisting of biologics and small molecules targeting multiple therapeutic indications for dogs and cats, each of which represents a potential breakthrough for veterinary medicine,” said Steven St. Peter, Aratana’s president and CEO.

“Looking ahead, we are focused on advancing our pipeline and commercial operations, while continuing to expand our portfolio via potential in-licensing and acquisition opportunities.”

The Animal Pharm award is just the latest bit of good news for Aratana.

The U.S. Department of Agriculture recently granted a full license for Aratana’s new treatment aiding dogs with B-cell lymphoma.

Thanks to positive study results, the company also plans to move forward with a new drug that helps dogs suffering from osteoarthritis, pending approval from the FDA. (That approval could come in 2016, the company said.)

And Aratana has launched a field study of another drug, this one for mitigating the pain that dogs feel after surgery.

“The ‘Best Pipeline 2014’ award from Animal Pharm is very gratifying for Aratana as it highlights our ability to take a truly unique vision—transforming the pet therapeutics industry through the development and commercialization of innovative biopharmaceutical products—and make it a reality,” St. Peter said.